SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 9:45 a.m. Pacific Time. Live audio webcasts of the company's presentations will be available by visiting Veracyte's website at http://investor.veracyte.com/events-presentations. A replay of the webcast will be available for 30 days following the conclu.
VCYT, IDXX and ISRG ride on genAI-powered growth as medical instruments evolve, even with weak industry returns and cost pressures.
Teleflex (NYSE: TFX - Get Free Report) and Veracyte (NASDAQ: VCYT - Get Free Report) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends. Profitability This table compares Teleflex and Veracyte's net margins,
Assenagon Asset Management S.A. decreased its position in Veracyte, Inc. (NASDAQ: VCYT) by 96.7% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 27,038 shares of the biotechnology company's stock after selling 803,061 shares during the period. Assenagon Asset Management
VCYT's Afirma and Decipher fuel strong test volume growth and a debt-free balance sheet, but rising macro costs and expenses temper the outlook.
Fisher Asset Management LLC lowered its position in Veracyte, Inc. (NASDAQ: VCYT) by 11.0% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 755,316 shares of the biotechnology company's stock after selling 93,297 shares during the quarter. Fisher Asset Management
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Nanovibronix (NASDAQ: NAOV - Get Free Report) and Veracyte (NASDAQ: VCYT - Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability and analyst recommendations. Analyst Recommendations This is a breakdown of recent ratings and
Advantage Alpha Capital Partners LP lessened its position in shares of Veracyte, Inc. (NASDAQ: VCYT) by 27.2% in the second quarter, according to its most recent filing with the SEC. The firm owned 19,123 shares of the biotechnology company's stock after selling 7,161 shares during the quarter. Advantage Alpha Capital Partners LP's holdings
AXQ Capital LP bought a new position in shares of Veracyte, Inc. (NASDAQ: VCYT) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 9,080 shares of the biotechnology company's stock, valued at approximately $245,000. Other hedge funds and other institutional
